Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma

Table 1 Patient characteristics and prognosis

Patient	Dose	Age	Sex	P/R	Curative	MTD	Tumor no.	Tumor	Background liver		CP	ALT	PLT	Prognosis
no.					treatment			histology	F	A				2 yrs	4.5 yrs
1	300	70	F	P	RFA	15	2	m-p	4	2	A	112	7.9	Rec	Rec
2	600	72	F	R	RFA	20	2	w	4	2	A	40	7.9	Rec	Rec λ
3	300	58	M	P	resection	25	1	m-p	2	1	A	16	19.2	nonRec	nonRec
4	600	54	M	P	resection	25	1	m-p	3	2	A	57	16.4	nonRec	Rec
5	600	60	F	P	RFA	23	1	m-p	4	2	B	23	6.4	nonRec	nonRec
6	300	73	F	P	RFA	20	2	m-p	3	2	A	31	14.2	Rec	Rec λ
7	300	69	F	P	RFA	11	3	w-m	4	1	A	38	11.5	Rec	Rec λ
8	600	74	F	P	RFA	16	2	m-p	4	1	A	45	5.1	nonRec	Rec
9	600	65	M	R	RFA	10	1	m-p	2	1	A	29	16.5	nonRec	nonRec
10	600	59	M	P	resection	34	1	m-p	4	2	B	60	9.4	nonRec	nonRec
11	300	70	F	R	RFA	15	1	w-m	4	2	B	98	7	nonRec	nonRec
12	300	66	M	P	RFA	15	1	m-p	4	1	A	90	10.6	nonRec	nonRec

Dose (mg/day), ALT(U/L), PLT(×10⁴/μL), MTD (mm).
F; female, M; male, P; primary HCC, R; (first) recurrent HCC, MTD; maximum tumor diameter, w; well-differentiated, m; moderately differentiated, p; poorly differentiated, F; fibrosis stage, A; activity grade, CP; Child-Pugh classification, ALT; alanine aminotransferase, PLT; platelet.
Rec; recurrence, nonRec; non-recurrence, λ; death.

ISSN: 1471-2407